| Ident. | Authors (with country if any) | Title |
|---|
| 000237 (2014) |
Kaouther Ben Abdelghani [Tunisie] ; Alia Fazaa [Tunisie] ; Leila Souabni [Tunisie] ; Leith Zakraoui [Tunisie] | Reactive arthritis induced by intravesical BCG therapy for bladder cancer |
| 000331 (2013) |
Mark C. Genovese [États-Unis] ; Roy M. Fleischmann [États-Unis] ; Maria Greenwald [États-Unis] ; Julie Satterwhite [États-Unis] ; Melissa Veenhuizen [États-Unis] ; Li Xie [États-Unis] ; Pierre-Yves Berclaz [États-Unis] ; Stephen Myers [États-Unis] ; Olivier Benichou [États-Unis] | Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors |
| 000337 (2013) |
Sarah L. Mackie [Royaume-Uni] ; Christian D. Mallen [Royaume-Uni] | Polymyalgia rheumatica |
| 000346 (2013) |
C. Malattia [Italie] ; A. Consolaro [Italie] ; S. Pederzoli [Italie] ; A. Madeo [Italie] ; A. Pistorio [Italie] ; M. Mazzoni [Italie] ; C. Mattiuz [Italie] ; Gm Magnano [Italie] ; S. Viola [Italie] ; A. Buoncompagni [Italie] ; E. Palmisani [Italie] ; R. Hasija [Italie] ; N. Ruperto [Italie] ; A. Ravelli [Italie] ; A. Martini [Italie] | MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis |
| 000352 (2013) |
Yvonne C. Lee [États-Unis] ; Bing Lu [États-Unis] ; Gilles Boire [Canada] ; Boulos Paul Haraoui [Canada] ; Carol A. Hitchon [Canada] ; Janet E. Pope [Canada] ; J Carter Thorne [Canada] ; Edward Clark Keystone [Canada] ; Daniel H. Solomon [États-Unis] ; Vivian P. Bykerk [États-Unis, Canada] | Incidence and predictors of secondary fibromyalgia in an early arthritis cohort |
| 000358 (2013) |
Tsutomu Takeuchi [Japon] ; Masayoshi Harigai [Japon] ; Yoshiya Tanaka [Japon] ; Hisashi Yamanaka [Japon] ; Naoki Ishiguro [Japon] ; Kazuhiko Yamamoto [Japon] ; Nobuyuki Miyasaka [Japon] ; Takao Koike [Japon] ; Minoru Kanazawa [Japon] ; Takuya Oba [Japon] ; Toru Yoshinari [Japon] ; Daniel Baker [États-Unis] | Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through 24 weeks |
| 000360 (2013) |
Marieke H. Otten [Pays-Bas] ; Janneke Anink [Pays-Bas] ; Sandra Spronk [Pays-Bas] ; Lisette W A. Van Suijlekom-Smit [Pays-Bas] | Efficacy of biological agents in juvenile idiopathic arthritis: a systematic review using indirect comparisons |
| 000362 (2013) |
John D. Isaacs [Royaume-Uni] ; Stanley B. Cohen [États-Unis] ; Paul Emery [Royaume-Uni] ; Paul P. Tak [Pays-Bas, Royaume-Uni] ; Jianmei Wang [Royaume-Uni] ; Guiyuan Lei [Royaume-Uni] ; Sarah Williams [Royaume-Uni] ; Preeti Lal [États-Unis] ; Simon J. Read [Royaume-Uni] | Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis |
| 000364 (2013) |
Sarah Louise Mackie [Royaume-Uni] ; Colin Thomas Pease [Royaume-Uni] | Diagnosis and management of giant cell arteritis and polymyalgia rheumatica: challenges, controversies and practical tips |
| 000367 (2013) |
Paul P. Tak [Royaume-Uni] ; Andra Balanescu [Roumanie] ; Vira Tseluyko [Ukraine] ; Silvia Bojin [Roumanie] ; Edit Drescher [Hongrie] ; Dan Dairaghi [États-Unis] ; Shichang Miao [États-Unis] ; Vittorio Marchesin [États-Unis] ; Juan Jaen [États-Unis] ; Thomas J. Schall [États-Unis] ; Pirow Bekker [États-Unis] | Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial |
| 000372 (2013) |
Maxime Dougados [France] ; Karsten Kissel [Suisse] ; Tom Sheeran [Royaume-Uni] ; Paul P. Tak [Pays-Bas] ; Philip G. Conaghan [Royaume-Uni] ; Emilio Martín Mola [Espagne] ; Georg Schett [Allemagne] ; Howard Amital [Israël] ; Federico Navarro-Sarabia [Espagne] ; Antony Hou [États-Unis] ; Corrado Bernasconi [Suisse] ; Twj Huizinga [Pays-Bas] | Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY) |
| 000520 (2013) |
A. Pfeil ; J. Böttcher [Allemagne] ; P. Oelzner ; G. Wolf | THU0123 Periarticular Demineralization as Measured by Digital X-Ray Radiogrammetry in Patients with Rheumatoid Arthritis – A Meta-Analysis |
| 000646 (2013) |
R. Fleischmann [États-Unis] ; S. Fiore ; C. Fan ; D. Thompson [États-Unis] | SAT0136 Sarilumab, a Fully Human Mab Against IL-6R Alpha, Subcutaneously-Administered Shows Significant Improvement in Ra Patients as Early as 2 Weeks: A Time to Event Analysis for Acr50 and Eular Good Response |
| 000711 (2013) |
Ruchika Goel [Inde] ; Debashish Danda [Inde] ; Sathish Kumar [Inde] ; George Joseph [Inde] | Rapid control of disease activity by tocilizumab in 10 ‘difficult‐to‐treat’ cases of Takayasu arteritis |
| 000840 (2013) |
Genevieve Tyra Ostring [Nouvelle-Zélande] ; Davinder Singh-Grewal [Australie] | Juvenile idiopathic arthritis in the new world of biologics |
| 000938 (2013) |
S. Miyauchi ; K. Umekita ; T. Hidaka [Japon] ; Y. Hashiba [Japon] ; T. Kawaguchi ; M. Matsuda ; K. Kubo ; S. Ueno ; N. Kusumoto ; I. Takajo ; Y. Kai [Japon] ; Y. Nagatomo ; A. Okayama | FRI0194 Treatment with anti-tumor necrosis factor (TNF) biologics to human t-lymphotropic virus type 1 (HTLV-1) positive patients with rheumatoid arthritis (RA): a case-control study |
| 000A50 (2013) |
| Abstracts |
| 000D27 (2013) |
C. Diaz-Torne ; M. A. Ortiz ; M. V. Hernandez [Espagne] ; D. Reina ; I. Castellví ; D. De La Fuente ; B. Magallares ; J. M. Ruiz-Martin ; H. Corominas [Espagne] ; C. Geli ; R. Sanmartí [Espagne] ; J. M. Llobet ; S. Vidal | AB0301 Characteristics of rheumatoid arthritis patients with adverse effects after the initiation of tocilizumab therapy |
| 000D28 (2013) |
A. Watik [Maroc] ; W. Rachidi [Maroc] ; S. Janani [Maroc] ; O. Mkinsi [Maroc] | AB0300 Efficacy of rituximab in the treatment of rheumatoid arthritis in moroccan patients tnf alpha inhibitor-naive: a prospective study |
| 000D29 (2013) |
A. S. Avdeeva [Russie] ; E. N. Alexandrova [Russie] ; A. V. Smirnov [Russie] ; A. A. Novikov [Russie] ; M. V. Cherkasova [Russie] ; E. Y. Panasyuk [Russie] ; E. L. Nasonov [Russie] | AB0299 Association of basal level antibodies to modified citrullinated vimentin (anti-mcv) with joint destruction in rheumatoid arthritis (ra) patients during the tocilizumab (tcz) therapy |
| 000D30 (2013) |
A. Gardette ; S. Ottaviani ; F. Tubach ; P. Nicaise-Roland [France] ; E. Palazzo ; G. Gill ; O. Meyer ; P. Dieudé | AB0298 High level of anti-ccp antibodies is predictive of good response to rituximab in patients with active rheumatoid arthritis. |
